Mode
Text Size
Log in / Sign up

Stimulant use is associated with increased social needs and severity in patients with opioid use disorderStimulant use linked to harder road for opioid treatment

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note the association between stimulant use and increased severity and lower treatment engagement in opioid use disorder.

Researchers examined the impact of cocaine and methamphetamine use on patients with opioid use disorder who also presented with depression or posttraumatic stress disorder. The study compared patients based on the frequency of stimulant use to evaluate associations with social needs, disease severity, and treatment engagement.

Findings indicated that patients who used stimulants were associated with higher levels of unmet social needs, including issues with education, housing, and legal problems. Furthermore, these patients exhibited greater severity of opioid use disorder and more severe symptoms of depression and posttraumatic stress disorder. Conversely, the data suggested that stimulant users were less likely to utilize medication for opioid use disorder or receive formal therapy.

A primary limitation of this research is its cross-sectional design, which allows for the identification of associations but cannot establish a causal relationship between stimulant use and clinical outcomes. Clinicians may find these results useful when identifying patients who may require more intensive social support and integrated mental health services. However, the findings should be interpreted with caution due to the observational nature of the data.

Managing opioid use disorder is complicated enough, but adding mental health struggles like depression or PTSD makes the road even harder. New data from 737 primary care patients shows that those who also use stimulants, such as cocaine or methamphetamine, face significant hurdles. These patients reported more severe symptoms of mental illness and higher risks of overdose compared to those who did not use stimulants.

Beyond the physical symptoms, the study found that stimulant use is linked to more unmet social needs. These patients faced more challenges with housing, education, and legal problems. These barriers can make it much harder to stay stable and find consistent support.

Perhaps most concerning is that those using stimulants were less likely to receive essential treatments. They had lower rates of medication for opioid use disorder and less access to therapy. Because this was a cross-sectional study, we can see a clear link between stimulant use and harder outcomes, even if we cannot say one directly causes the other. Doctors can use these findings to better identify which patients need extra support to overcome these overlapping hurdles.

What this means for you:
Patients using both opioids and stimulants face more severe mental illness and have less access to treatment.

Common questions

How does stimulant use affect opioid treatment?

Patients who used cocaine or methamphetamine were less likely to receive medication for opioid use disorder and had lower rates of therapy. They also faced more severe symptoms of depression and PTSD compared to those who did not use stimulants.

What other risks are linked to stimulant use?

The study found that stimulant users had a higher risk of overdose and more severe opioid use disorder. They also reported more unmet social needs, including more issues with housing, education, and legal problems.

Who was included in this study?

The study included 737 primary care patients who had an opioid use disorder along with co-occurring depression and or posttraumatic stress disorder (PTSD).

Study Details

Study typeRct
EvidenceLevel 2
PublishedSep 2026
View Original Abstract ↓
BACKGROUND: Among individuals with opioid use disorder (OUD) and co-occurring mental illness, stimulant co-use may be associated with more severe symptoms and less treatment utilization. We sought to understand the association of stimulant use with social needs and OUD and mental illness severity and treatment. METHODS: This cross-sectional study used baseline data from a randomized controlled trial of collaborative care for primary care patients with OUD and co-occurring depression and/or posttraumatic stress disorder (PTSD). We categorized stimulant use (cocaine/methamphetamine) into daily use (20 or more days), non-daily use (1-19 days), and no use (0 days). We conducted comparisons across measures of social needs and OUD and mental illness severity and treatment through one-way analysis of variance for continuous variables and chi-square tests for categorical/binary variables. RESULTS: 123 (15.4%) participants used stimulants daily, 164 (20.6%) reported non-daily use, and 510 (64%) used no stimulants. When comparing participants by stimulant use, we found differences in education (p = 0.020), housing status (p < 0.001), legal problems (p < 0.001), recent overdose (p < 0.001), overdose risk (p < 0.001), MOUD use (p < 0.001), depression/PTSD symptoms (p < 0.001), and receipt of therapy (p = 0.004) or medication (p < 0.001) for depression/PTSD with all differences demonstrating more unmet social needs, greater OUD and mental illness severity, and lower treatment utilization for participants using stimulants. CONCLUSIONS: Among primary care patients with OUD and co-occurring depression/PTSD, individuals using stimulants experienced a higher disease burden and decreased utilization of care across multiple measures. These associations suggest that clinicians should specifically address stimulant use in the context of co-occurring OUD and mental illness.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.